The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Clinical Roundup

TriSalus, UColorado Anschutz Medical Campus to collaborate on immuno-oncology treatments for liver and pancreatic tumors

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

TriSalus Life Sciences and the University of Colorado Anschutz Medical Campus entered a strategic research collaboration to advance research of immuno-oncology treatments for patients with liver and pancreatic tumors. 

Over the next three years, TriSalus will collaborate with the University of Colorado Anschutz Medical Campus on studies using TriSalus’ proprietary Pressure-Enabled Drug Delivery (PEDD) method for the administration of an investigational toll-like receptor 9 (TLR9) agonist, SD-101.

TriSalus’ platform consists of an investigational immunotherapy, SD-101, that aims to reactivate the immune system within these organs for targeted tumor killing, and the PEDD method, which modulates pressure and flow within blood vessels to improve therapy uptake and tumor response.

CU Innovations has led the establishment of the business relationship while the CU Anschutz research team will focus on creating clinical research to advance TriSalus’ approach.  

Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Daraxonrasib improves OS across metastatic pancreatic cancer subgroups, phase III RASolute 302 trial finds

Rasonque (daraxonrasib) consistently provided an overall survival benefit compared with chemotherapy across all evaluated RAS genotype subgroups among patients with previously treated metastatic pancreatic adenocarcinoma, including those with no identified tumor RAS mutation, according to exploratory subgroup analyses from the phase III RASolute 302 trial.
Clinical Roundup

Camupepimut demonstrated favorable treatment effect trends in pancreatic cancer, phase II AMPLIFY-7P study finds

Camupepimut (ELI-002 7P) demonstrated consistent and favorable treatment-effect trends in patients with and without detectable baseline ctDNA and in patients without prior radiation across multiple pre-specified analyses, according to the results of a randomized phase II study of patients with resected pancreatic ductal adenocarcinoma called AMPLIFY-7P. 
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account